MedTrace Logo

Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study

NCT00495820 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-11-20

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine the efficacy of methylphenidate over placebo in treating apathy in patients with Alzheimer's dementia. Apathy is one of the earliest and most profound disturbances that occur in Alzheimer's dementia (AD).

Hypotheses: 1. Methylphenidate (MPH) will improve apathy significantly more than placebo in AD.

2\. Successful treatment of apathy will improve Instrumental Activities of Daily Living (IADLs), and caregiver burden.

Conditions

Interventions

DRUG

Methylphenidate

Subject will receive 5mg twice a day for two weeks then 10mg twice a day until week 12 of the study.

OTHER

Placebo

Standard inactive pill.

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Prasad R. Padala · VA Medical Center, Omaha

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2010-03-31
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00495820 on ClinicalTrials.gov